- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01209000
신증후군 연구 네트워크 (NEPTUNE)
희귀 질환 임상 연구 네트워크 하의 신증후군 연구 네트워크
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not surprising that the available therapies are imperfect. The therapies lack a clear biological basis, and as many families have experienced, they are often not beneficial, and in fact may be significantly toxic. Given these observations, it is essential that research be conducted that address these serious obstacles to effectively caring for patients.
In response to a request for applications by the National Institutes of Health, Office of Rare Diseases (NIH, ORD) for the creation of Rare Disease Clinical Research Consortia, a number of affiliated universities joined together with The NephCure Foundation the NIDDK, the ORDR, and the University of Michigan in collaboration towards the establishment of a Nephrotic Syndrome (NS) Rare Diseases Clinical Research Consortium.
Through this consortium the investigators hope to understand the fundamental biology of these rare diseases and aim to bank long-term observational data and corresponding biological specimens for researchers to access and further enrich.
연구 개요
상세 설명
Idiopathic Nephrotic Syndrome (NS) is a rare disease syndrome responsible for approximately 12% of all causes of end-stage kidney disease (ESRD) and up to 20% of ESRD in children. Treatment strategies for Focal and Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD) and Membranous Nephropathy (MN), the major causes of NS, include high dose prolonged steroid therapy, cyclophosphamide, cyclosporine A, tacrolimus, mycophenolate mofetil and other immunosuppressive agents, which all carry significant side effects. Failure to obtain remission using the current treatment approaches frequently results in progression to ESRD with its associated costs, morbidities, and mortality. In the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry, half of the pediatric patients with Steroid Resistant Nephrotic Syndrome required renal replacement therapy within two years of being enrolled in the disease registry. FSGS also has a high recurrence rate following kidney transplantation (30-40%) and is the most common recurrent disease leading to allograft loss.
The prevailing classification of Nephrotic Syndrome categorizes patients into FSGS, MCD, and MN, if in the absence of other underlying causes, glomerular histology shows a specific histological pattern. This classification does not adequately predict the heterogeneous natural history of patients with FSGS, MCD, and MN. Major advances in understanding the pathogenesis of FSGS and MCD have come over the last ten years from the identification of several mutated genes responsible for causing Steroid Resistant Nephrotic Syndrome (SRNS) presenting with FSGS or MCD histopathology in humans and model organisms. These functionally distinct genetic disorders can present with indistinguishable FSGS lesions on histology confirming the presence of heterogeneous pathogenic mechanisms under the current histological diagnoses.
The limited understanding of FSGS, MCD, and MN biology in humans has necessitated a descriptive classification system in which heterogeneous disorders are grouped together. This invariably consigns these heterogeneous patients to the same therapeutic approaches, which use blunt immunosuppressive drugs that lack a clear biological basis, are often not beneficial, and are complicated by significant toxicity. The foregoing shortcomings make a strong case that concerted and innovative investigational strategies combining basic science, translational, and clinical methods should be employed to study FSGS, MCD, and MN. It is for these reasons that the Nephrotic Syndrome Study Network is established to conduct clinical and translational research in patients with FSGS/MCD and MN.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Chrysta C. Lienczewski, BS
- 전화번호: 734-615-5021
- 이메일: NEPTUNE-Study@umich.edu
연구 연락처 백업
- 이름: Amanda Williams, BS
- 전화번호: 734-615-5017
- 이메일: NEPTUNE-Study@umich.edu
연구 장소
-
-
California
-
Los Angeles, California, 미국, 90227
- 모병
- University of Southern California-Children's Hospital
-
수석 연구원:
- Kevin Lemley, MD, PhD
-
연락하다:
- Sharon Tang, BSN
- 전화번호: 323-361-7299
- 이메일: shatang@chla.usc.edu
-
Palo Alto, California, 미국, 94304
- 모병
- Stanford University School of Medicine
-
연락하다:
- Kshama Mehta, PhD
- 전화번호: 650-736-1822
- 이메일: krmehta@stanford.edu
-
수석 연구원:
- Richard Lafayette, MD
-
San Francisco, California, 미국, 94158
- 아직 모집하지 않음
- University of California San Francisco Benioff Children's Hospitals
-
수석 연구원:
- Paul Brakeman, MD, PhD
-
연락하다:
- Daniel Schrader
- 이메일: daniel.schrader@ucsf.edu
-
Torrance, California, 미국, 90502
- 모병
- Lundquist Biomedical Research Institute at Harbor UCLA Medical Center
-
연락하다:
- Janine LaPage
- 전화번호: 310-222-4104
- 이메일: jlapage@labiomed.org
-
수석 연구원:
- Sharon Adler, MD
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 아직 모집하지 않음
- Children's Hospital Colorado
-
연락하다:
- Nathan Rogers
- 이메일: Nathan.Rogers@childrenscolorado.org
-
부수사관:
- Gabriel Cara-Fuentes, MD
-
Aurora, Colorado, 미국, 80045
- 아직 모집하지 않음
- University of Colorado Anschutz School of Medicine
-
수석 연구원:
- Amber Podoll, MD
-
연락하다:
- Elizabeth Wagner
- 이메일: elizabeth.c.wagner@cuanschutz.edu
-
-
Florida
-
Miami, Florida, 미국, 33136
- 모병
- University of Miami Miller School of Medicine
-
연락하다:
- Carlos Bidot
- 전화번호: 305-243-8973
- 이메일: cbidot2@miami.edu
-
수석 연구원:
- Alessia Fornoni, MD. PhD
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- 모병
- Emory University and Children's Healthcare of Atlanta
-
수석 연구원:
- Laurence Greenbaum, MD, PhD
-
연락하다:
- Emily Yun
- 전화번호: 404-712-9998
- 이메일: emily.yun@emory.edu
-
-
Illinois
-
Chicago, Illinois, 미국, 60680
- 모병
- John Stroger Cook County Hospital
-
연락하다:
- Mathew Itteera
- 전화번호: 312-864-4614
- 이메일: mitteera@cookcountyhhs.org
-
수석 연구원:
- Ambarish Athavale, MD
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- 모병
- University of Kansas Medical Center
-
연락하다:
- Catherine Creed
- 이메일: ccreed@kumc.edu
-
수석 연구원:
- Ellen McCarthy, MD
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- 모병
- Johns Hopkins Medical Institute
-
연락하다:
- Sara Boynton
- 전화번호: 443-287-9051
- 이메일: sboynto3@jhmi.edu
-
수석 연구원:
- Alicia Neu, MD
-
부수사관:
- Michael Choi, MD
-
Bethesda, Maryland, 미국, 20892
- 완전한
- Kidney Disease Section, NIDDK, NIH
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- University of Michigan Medical Center
-
연락하다:
- Chrysta C. Lienczewski, BS - adult
- 전화번호: 734-615-5021
- 이메일: boridley@med.umich.edu
-
수석 연구원:
- Matthias Kretzler, MD
-
연락하다:
- Amanda Williams, BS - adult
- 전화번호: 734-615-5017
- 이메일: amwi@umich.edu
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- CS Mott Children's Hospital, University of Michigan
-
부수사관:
- Debbie Gipson, MD, MS
-
연락하다:
- Hailey Desmond, MS
- 전화번호: 734-232-4851
- 이메일: heturner@umich.edu
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- 완전한
- Mayo Clinic
-
-
Missouri
-
Kansas City, Missouri, 미국, 64108
- 모병
- Children's Mercy Hospital
-
수석 연구원:
- Tarak Srivastava, MD
-
연락하다:
- Kelsey Markus
- 이메일: kemarkus@cmh.edu
-
St Louis, Missouri, 미국, 63110
- 아직 모집하지 않음
- Washington University - St Louis
-
연락하다:
- Leslie Walther
- 이메일: leslie.walther@wustl.edu
-
수석 연구원:
- Vikas Dharnidharka, MD, PhD
-
-
New York
-
New Hyde Park, New York, 미국, 11040
- 모병
- Cohen Children's Hospital
-
수석 연구원:
- Christine Sethna, MD
-
연락하다:
- Suzanne Vento, BSN
- 전화번호: 718-470-3499
- 이메일: svento@northwell.edu
-
New York, New York, 미국, 10032
- 모병
- Columbia University Medical Center
-
수석 연구원:
- Andrew Bomback, MD, MPH
-
연락하다:
- Anup Pradhan
- 전화번호: 212-305-6842
- 이메일: arp2209@cumc.columbia.edu
-
New York, New York, 미국, 10010
- 모병
- New York University Medical Center
-
연락하다:
- Frank Modersitzki, MPH - adult
- 전화번호: 6379 212-686-7500
- 이메일: Frank.Modersitzki@va.gov
-
수석 연구원:
- Olga Zhadnova, MD
-
수석 연구원:
- Howard Trachtman, MD
-
연락하다:
- Laura Jane Pehrson - peds
- 이메일: laurajane.pehrson@nyulangone.org
-
New York, New York, 미국, 10016
- 모병
- Bellevue Hospital
-
연락하다:
- Frank Modersitzki, MPH
- 전화번호: 6379 212-686-7500
- 이메일: Frank.Modersitzki@va.gov
-
수석 연구원:
- Laura Barisoni, MD
-
부수사관:
- Olga Zhadnova, MD
-
New York, New York, 미국, 10016
- 모병
- New York University Veterans Administration
-
연락하다:
- Frank Modersitzki, MPH
- 전화번호: 6379 212-686-7500
- 이메일: Frank.Modersitzki@va.gov
-
수석 연구원:
- Laura Barisoni, MD
-
부수사관:
- Olga Zhadnova, MD
-
The Bronx, New York, 미국, 11040
- 모병
- Montefiore Medical Center
-
연락하다:
- Patti Flynn, RN
- 전화번호: 718-655-1120
- 이메일: pflynn@montefiore.org
-
부수사관:
- Robert Woroniecki, MD
-
수석 연구원:
- Frederick Kaskel, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27599
- 모병
- University of North Carolina at Chapel Hill
-
연락하다:
- Anne Froment
- 전화번호: 919-923-1382
- 이메일: Anne_Froment@med.unc.edu
-
수석 연구원:
- Patrick H. Nachman, MD
-
부수사관:
- Susan L. Hogan, PhD, MPH
-
부수사관:
- Keisha Gibson, MD
-
연락하다:
- Fernanda Ochoa
- 이메일: ferochoa@email.unc.edu
-
Charlotte, North Carolina, 미국, 28203
- 모병
- Atrium Health Levine Children's Hospital
-
수석 연구원:
- Susan Massengill, MD
-
연락하다:
- Layla Lo
- 이메일: nkauj.lo@atriumhealth.org
-
Winston-Salem, North Carolina, 미국, 27157
- 빼는
- Wake Forest School of Medicine
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195
- 모병
- Cleveland Clinic
-
부수사관:
- Katherine Dell, MD
-
연락하다:
- Stefanie Larson
- 이메일: larsons2@ccf.org
-
연락하다:
- Villarreal
-
Cleveland, Ohio, 미국, 44106
- 완전한
- University Hospital Rainbow Babies & Children's Hospital
-
Cleveland, Ohio, 미국, 44109
- 완전한
- MetroHealth Hospital at Case Western Medical Center
-
Columbus, Ohio, 미국, 43210
- 모병
- The Ohio State University Wexner Medical Center
-
연락하다:
- Alexander Price
- 이메일: alexander.price2@osumc.edu
-
수석 연구원:
- Salem Almaani, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- University of Pennsylvania
-
연락하다:
- Krishna Kallem, MD - adult, MS
- 전화번호: 484-358-0315
- 이메일: krishna.kallem@uphs.upenn.edu
-
수석 연구원:
- Lawrence Holzman, MD
-
연락하다:
- Aliya Edwards - peds
- 이메일: EdwardsA1@chop.edu
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- Children's Hospital of Philadelphia
-
부수사관:
- Kevin Meyers, MD
-
연락하다:
- Alilya Edwards
- 이메일: EdwardsA1@chop.edu
-
Philadelphia, Pennsylvania, 미국, 19140
- 모병
- Temple University
-
연락하다:
- Zoe Pfeffer, BS
- 전화번호: 215-707-4712
- 이메일: zoe.pfeffer@tuhs.temple.edu
-
수석 연구원:
- Crystal Gadegbeku, MD
-
수석 연구원:
- Iris Lee, MD
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- 모병
- Medical University of South Carolina
-
수석 연구원:
- David Selewski, MD, MS
-
-
Texas
-
Dallas, Texas, 미국, 75390
- 모병
- University of Texas-Southwestern
-
수석 연구원:
- Kamal Sambandam, MD
-
연락하다:
- Elizabeth Robles
- 이메일: elizabeth.robles@utsouthwestern.edu
-
Houston, Texas, 미국, 77030
- 모병
- Texas Children's Hospital - Baylor College of Medicine
-
연락하다:
- Aisha Deslandes
- 이메일: aisha.deslandes@bcm.edu
-
수석 연구원:
- Shweta S. Shah, MD
-
-
Washington
-
Seattle, Washington, 미국, 98195
- 모병
- University of Washington
-
수석 연구원:
- Peter J. Nelson, MD
-
연락하다:
- Linda Manahan, BSN
- 이메일: lmanahan@nephrology.washington.edu
-
Seattle, Washington, 미국, 98145
- 모병
- Seattle Children's Hospital
-
부수사관:
- Sangeeta Hingorani, MD
-
연락하다:
- Emily Pao
- 이메일: emily.pao@seattlechildrens.org
-
Spokane, Washington, 미국, 99204
- 모병
- Providence Medical Research Center
-
연락하다:
- Ann Cooper, CCRC
- 전화번호: 509-474-4327
- 이메일: Ann.Cooper@providence.org
-
부수사관:
- Katherine Tuttle, MD
-
연락하다:
- Kelli Kuykendall, CCRC
- 전화번호: 509-474-4320
- 이메일: Kelli.Kuykendall@providence.org
-
-
-
-
Ontario
-
Richmond Hill, Ontario, 캐나다, L4C 4Z3
- 완전한
- York Central Hospital
-
Scarborough Village, Ontario, 캐나다, M1H 3G4
- 완전한
- Scarborough Hospital
-
Toronto, Ontario, 캐나다, M4N 3M5
- 모병
- Sunnybrook Hospital
-
수석 연구원:
- Michelle Hladunewich, MD
-
연락하다:
- Rhea O'Neill
- 이메일: rhea.oneill@sri.utoronto.ca
-
Toronto, Ontario, 캐나다, L5M 2N1
- 모병
- Credit Valley Hospital
-
부수사관:
- Phillip Boll, MD
-
연락하다:
- Martin Romano, MD
- 전화번호: 416-340-3514
- 이메일: martin.romano@thp.ca
-
Toronto, Ontario, 캐나다, M5G2C4
- 모병
- University Health Network
-
연락하다:
- Paul Ling, MD
- 전화번호: 416-340-3514
- 이메일: pling@uhnresearch.ca
-
연락하다:
- Martin Romano, MD
- 이메일: Martin.Romano@trilliumhealthpartners.ca
-
수석 연구원:
- Daniel Cattran, MD
-
부수사관:
- Heather Reich, MD
-
부수사관:
- Michelle Hladunewich, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Patients with signs and symptoms of kidney disease consistent with FSGS, MCD, MN or proteinuric renal disease or pediatric participants not previously biopsied, who present for patient care at participating clinical centers will be eligible for Cohort A (biopsy cohort) study population targeted for enrollment into the NEPTUNE study.
To establish a cohort of pediatric participants with incident nephrotic syndrome, Cohort B, a non-biopsy cohort has been initiated for Protocol V4.0. This population, <19 years of age, presenting for nephrotic syndrome and less than 30 days of immunosuppression therapy exposure, will also be targeted for enrollment into the cNEPTUNE study.
Potential participants willing to receive their initial care and subsequent follow-up study visits at one of these sites are welcome to participate.
설명
Cohort A (biopsy cohort) Inclusion Criteria:
Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting the following inclusion criteria:
- Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening/eligibility visit.
- Scheduled renal biopsy
Cohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:
-
Age <19 years of age
-
Initial presentation with <30 days immunosuppression therapy
-
Proteinuria/nephrotic
- UA>2+ and edema OR
- UA>2+ and serum albumin <3 OR
- UPC > 2g/g and serum albumin <3
Exclusion Criteria (Cohort A&B):
- Prior solid organ transplant
- A clinical diagnosis of glomerulopathy without diagnostic renal biopsy
- Clinical, serological or histological evidence of systemic lupus erythematosus (SLE) as defined by the ARA criteria. Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Pathology Society categories of lupus nephritis, and frequently overlaps with other classification categories of SLE nephritis (68)
- Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas), genito-urinary malformations with vesico-urethral reflux or renal dysplasia)
- Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months
- Unwillingness or inability to give a comprehensive informed consent
- Unwillingness to comply with study procedures and visit schedule
- Institutionalized individuals (e.g., prisoners)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
FSGS/MCD Cohort (Cohort A)
Focal Segmental Glomerulosclerosis/Minimal Change Disease (FSGS/MCD) Cohort Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for FSGS or MCD. Eligible participants must be scheduled for a clinically indicated renal biopsy. |
Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete. |
|
MN Cohort (Cohort A)
Membranous Nephropathy (MN) Cohort Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for MN. Eligible participants must be scheduled for a clinically indicated renal biopsy. |
Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete. |
|
Other glomerulopathies cohort
Participants enrolled in NEPTUNE and determined to not have FSGS/MCD or MN will be followed in a third group. Eligible participants must be scheduled for a clinically indicated renal biopsy. |
Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete. |
|
cNEPTUNE (Cohort B)
Participants < 19 years of age, with < 30 days exposure to immunosuppression therapy who are not scheduled for renal biopsy. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Event rate of change in urinary protein excretion and renal function.
기간: 60 months
|
Defined as remission, partial remission and non-remission |
60 months
|
|
Rate of change in renal function.
기간: 60 months
|
Defined as:
|
60 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Quality of Life:
기간: 60 months
|
Patient-reported outcome will be assessed using Quality of Life questionnaires at regular intervals as stipulated in the visit calendar using the SF-36, PedsQL and the Patient Reported Outcome Measurement Information System (PROMIS) (in the age-appropriate groups). |
60 months
|
|
Malignancies
기간: 60 months
|
Any cancer diagnosis of the skin, hematopoietic system, or solid organ after enrollment in NEPTUNE |
60 months
|
|
Infections, Serious and Systemic
기간: 60 months
|
Infections including one of the following:
|
60 months
|
|
Thromboembolic Events
기간: 60 months
|
Documented diagnosis of one of the following:
|
60 months
|
|
Hospitalization
기간: 60 months
|
Documented hospital admission, including observation for ≥24 hours. |
60 months
|
|
Emergency Department/ Observation Unit Visit
기간: 60 months
|
Documented visit to an emergency department or observation unit that does not lead to hospitalization and is less than 24 hours. |
60 months
|
|
Acute Kidney Injury
기간: 60 months
|
Documented diagnosis of acute kidney injury as defined by the AKIN (Mehta et al., Critical Care 2007, 11:R31) and/or renal failure requiring renal replacement therapy <3 months. |
60 months
|
|
Death
기간: 60 months
|
|
60 months
|
|
New Onset Diabetes
기간: 60 months
|
Diagnosis of diabetes as indicated by 1 or more of the following not present at NEPTUNE Enrollment:
|
60 months
|
공동 작업자 및 조사자
협력자
수사관
- 수석 연구원: Matthias Kretzler, MD, University of Michigan
간행물 및 유용한 링크
일반 간행물
- Wang CS, Troost JP, Wang Y, Greenbaum LA, Gibson K, Trachtman H, Srivastava T, Reidy K, Kaskel F, Sethna CB, Meyers K, Dell KM, Tran CL, Hingorani S, Lemley KV, Lin JJ, Gipson DS. Determinants of medication adherence in childhood nephrotic syndrome and associations of adherence with clinical outcomes. Pediatr Nephrol. 2022 Jul;37(7):1585-1595. doi: 10.1007/s00467-021-05176-8. Epub 2021 Nov 18.
- Solagna F, Tezze C, Lindenmeyer MT, Lu S, Wu G, Liu S, Zhao Y, Mitchell R, Meyer C, Omairi S, Kilic T, Paolini A, Ritvos O, Pasternack A, Matsakas A, Kylies D, Wiesch JSZ, Turner JE, Wanner N, Nair V, Eichinger F, Menon R, Martin IV, Klinkhammer BM, Hoxha E, Cohen CD, Tharaux PL, Boor P, Ostendorf T, Kretzler M, Sandri M, Kretz O, Puelles VG, Patel K, Huber TB. Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs. J Clin Invest. 2021 Jun 1;131(11):e135821. doi: 10.1172/JCI135821.
- Kang H, Kim DR, Jung YH, Baek CW, Park YH, In Oh J, Kim WJ, Choi GJ. Pre-warming the Streamlined Liner of the Pharynx Airway (SLIPA) improves fitting to the laryngeal structure: a randomized, double-blind study. BMC Anesthesiol. 2015 Nov 20;15:167. doi: 10.1186/s12871-015-0151-4.
- Hogan MC, Lieske JC, Lienczewski CC, Nesbitt LL, Wickman LT, Heyer CM, Harris PC, Ward CJ, Sundsbak JL, Manganelli L, Ju W, Kopp JB, Nelson PJ, Adler SG, Reich HN, Holzmann LB, Kretzler M, Bitzer M. Strategy and rationale for urine collection protocols employed in the NEPTUNE study. BMC Nephrol. 2015 Nov 17;16:190. doi: 10.1186/s12882-015-0185-3.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- 6801
- 1U54DK083912 (미국 NIH 보조금/계약)
- 1R01DK141114-01A1 (미국 NIH 보조금/계약)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .